Insider Buying: TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Buys $25,300.90 in Stock

TriSalus Life Sciences, Inc. (NASDAQ:TLSI) CEO Mary T. Szela acquired 5,030 shares of the stock in a transaction dated Wednesday, January 29th. The stock was acquired at an average cost of $5.03 per share, with a total value of $25,300.90. Following the transaction, the chief executive officer now owns 439,249 shares of the company’s stock, valued at approximately $2,209,422.47. This trade represents a 1.16 % increase in their ownership of the stock. The purchase was disclosed in a document filed with the SEC, which can be accessed through the SEC website.

TriSalus Life Sciences Stock Performance

Shares of NASDAQ TLSI opened at $5.11 on Monday. The stock has a fifty day moving average price of $4.60 and a 200 day moving average price of $4.75. TriSalus Life Sciences, Inc. has a 12-month low of $3.50 and a 12-month high of $10.42. The company has a market cap of $155.80 million, a P/E ratio of -2.05 and a beta of 0.51.

Institutional Investors Weigh In On TriSalus Life Sciences

A number of large investors have recently modified their holdings of the stock. Geode Capital Management LLC lifted its position in TriSalus Life Sciences by 45.4% during the 3rd quarter. Geode Capital Management LLC now owns 200,427 shares of the company’s stock worth $924,000 after acquiring an additional 62,542 shares in the last quarter. MSD Partners L.P. acquired a new position in shares of TriSalus Life Sciences during the third quarter worth $184,000. Walleye Capital LLC purchased a new position in shares of TriSalus Life Sciences in the third quarter valued at $66,000. Virtu Financial LLC acquired a new stake in TriSalus Life Sciences during the 3rd quarter valued at $92,000. Finally, Vestcor Inc purchased a new stake in TriSalus Life Sciences during the 3rd quarter worth $108,000. Institutional investors and hedge funds own 2.58% of the company’s stock.

Wall Street Analysts Forecast Growth

Several analysts have commented on TLSI shares. Cantor Fitzgerald initiated coverage on TriSalus Life Sciences in a report on Tuesday, December 17th. They issued an “overweight” rating and a $10.00 price target for the company. Roth Mkm restated a “buy” rating and issued a $11.00 target price on shares of TriSalus Life Sciences in a report on Friday, January 24th. Northland Capmk raised shares of TriSalus Life Sciences to a “strong-buy” rating in a research note on Friday, October 25th. Northland Securities assumed coverage on TriSalus Life Sciences in a report on Friday, October 25th. They set an “outperform” rating and a $12.50 price objective for the company. Finally, Roth Capital upgraded TriSalus Life Sciences to a “strong-buy” rating in a report on Monday, November 11th. Seven research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company’s stock. According to data from MarketBeat.com, the company has a consensus rating of “Buy” and a consensus target price of $11.79.

About TriSalus Life Sciences

TriSalus Life Sciences, Inc, a medical technology company, researches, develops, and sells drug delivery technologies and immune-oncology therapeutics for the treatment of liver and pancreatic cancer. The company offers Pressure Enabled Drug Delivery infusion systems, such as the TriNav infusion system, which is used in transarterial radioembolization and chemoembolization procedures for patients with liver cancer and metastases; and the Pancreatic Retrograde Venous Infusion device, which is in Phase 1 clinical trial, for locally advanced pancreatic cancer.